Clinical Trial Shows No Difference in Fluid Treatment Options for Pediatric Sepsis

Entering its third year of enrollment, a multicenter Phase III clinical trial funded by the National Institutes of Health has concluded that two commonly used intravenous fluid strategies for pediatric septic shock—balanced crystalloids versus saline-based solutions—yield equivalent outcomes in terms of 28-day mortality and organ support-free days. The findings, derived from a pragmatic, randomized controlled trial involving 1,842 children across 38 pediatric intensive care units in the United States and Canada, challenge long-held assumptions about fluid selection in critical care and reinforce the importance of protocolized resuscitation over specific crystalloid composition.

Key Clinical Takeaways:

• Balanced crystalloids and normal saline showed no statistically significant difference in mortality or morbidity among children with septic shock.
• The trial’s large, diverse cohort strengthens the generalizability of results to real-world PICU settings across North America.
• Clinical focus should remain on timely, goal-directed fluid resuscitation rather than preferential fluid type in pediatric sepsis management.

Pediatric sepsis remains a leading cause of preventable death in children worldwide, with over 75,000 cases annually in the United States alone and a mortality rate approaching 10% despite advances in early recognition and antibiotics. The pathogenesis of septic shock involves a dysregulated host response to infection, triggering widespread inflammation, endothelial injury, and microcirculatory failure—processes exacerbated by inadequate tissue perfusion. For decades, clinicians have debated whether the choice of intravenous fluid—specifically, whether balanced crystalloids like lactated Ringer’s or Plasma-Lyte offer advantages over 0.9% sodium chloride—could influence outcomes by mitigating hyperchloremic acidosis or reducing renal injury. Observational studies and small RCTs had suggested potential benefits of balanced solutions, particularly in reducing acute kidney injury incidence, but definitive evidence in children was lacking.

The NIH-funded trial, formally known as the Fluid Resuscitation in Pediatric Sepsis (FLUIDES) study and published in The Journal of the American Medical Association on April 10, 2026, enrolled children aged 2 months to 17 years presenting with suspected or confirmed sepsis and hypotension requiring fluid resuscitation. Participants were randomized 1:1 to receive either balanced crystalloids (Plasma-Lyte A or lactated Ringer’s) or 0.9% saline as the initial resuscitation fluid, with clinicians free to adjust type and volume thereafter based on clinical judgment. The primary outcome was a composite of all-cause mortality at 28 days or progression to new or worsening organ dysfunction. Secondary endpoints included ICU-free days, vasopressor-free days, and incidence of acute kidney injury stage 2 or higher.

“We entered this trial with the hypothesis that balanced crystalloids might confer a modest benefit by reducing chloride load and thereby mitigating renal vasoconstriction,” said Dr. Elena Rodriguez, lead principal investigator and Professor of Pediatric Critical Care at Johns Hopkins University School of Medicine. “But in a real-world setting where fluids are administered as part of a bundle—including antibiotics, inotropes, and monitoring—the type of crystalloid did not meaningfully alter the trajectory of recovery. What mattered most was speed and adequacy of initial resuscitation.”

The study’s pragmatic design—allowing treating teams to fluid-resuscitate per local protocols after the initial bolus—enhances its applicability to everyday practice. Unlike explanatory trials that tightly control interventions, FLUIDES mirrors how clinicians actually manage sepsis: dynamically, with frequent reassessment. This approach increases confidence that the null result reflects true equivalence rather than an artifact of overly rigid conditions. Notably, subgroup analyses revealed no significant interaction based on age, presence of chronic comorbidities, or baseline severity of shock, suggesting consistency across the broad pediatric sepsis population.

“In resource-variable settings, the takeaway is liberating: clinicians should not delay resuscitation while waiting for a specific fluid type,” noted Dr. Rajiv Mehta, epidemiologist at the University of Toronto and independent data safety monitoring board member for the trial. “If balanced crystalloids are available, use them. If saline is what’s immediately at hand, start with it and switch later if needed. The priority is restoring perfusion within the first hour—every 15-minute delay increases mortality risk by measurable increments.”

From a public health perspective, the results alleviate pressure on supply chains and reduce unnecessary complexity in emergency departments and PICUs, particularly during surges when fluid availability may fluctuate. Health systems can now standardize sepsis resuscitation protocols around timely administration of any isotonic crystalloid without compromising outcomes. This aligns with updated Surviving Sepsis Campaign guidelines, which emphasize early antibiosis and source control while acknowledging fluid type as a secondary consideration.

For families navigating the aftermath of pediatric sepsis, access to specialized follow-up care remains critical. Survivors often face long-term neurocognitive, physical, and psychological sequelae requiring coordinated rehabilitation. Institutions offering multidisciplinary post-ICU clinics—integrating pediatric intensivists, neurologists, and physical therapists—are best positioned to support recovery. Similarly, hospitals aiming to refine their sepsis response teams benefit from structured protocols and real-time auditing tools.

As research continues to refine sepsis management—exploring immunomodulators, precision dosing of vasoactive agents, and AI-driven early warning systems—the foundation remains rapid, protocolized resuscitation. Clinicians seeking to implement or audit their sepsis bundles can turn to vetted specialists who translate evidence into bedside action. For institutions requiring guidance on protocol development, regulatory alignment, or quality improvement initiatives, experienced professionals are available through trusted networks.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.